PepTalk - The Protein Science Week

January 8–12, 2018
San Diego, CA

Meet Genedata experts at PepTalk in San Diego, CA, USA.

Don't miss the opportunity to see how Genedata solutions efficiently support the whole biopharmaceutical R&D workflow, including screening and protein engineering, expression and purification, characterization and analysis of protein therapeutics, cell line design and development, bioprocess optimization, and quality control of biologicals.

To get more information about Genedata solutions, please contact info@genedata.com.

Recommended Oral Presentations

Platformization of Multi-Specific Protein Engineering I: From in silico Design and Bulk Modular Cloning to Automated Deconvolution of Variant Libraries
Joerg Birkenfeld, Ph.D., Section Head, High Throughput Biologics, R&D Biologics Research/Protein Therapeutics, Sanofi-Aventis Deutschland GmbH

Assessing and Ensuring Developability Session
Friday, January 12 | 9:05–9:35

The success rate to identify a multi-specific lead molecule with favorable drug-like properties increases with the number of variants tested. We report here the establishment of a novel, automated platform process for the fast generation of large panels of multi-specific variants (up to 10,000). Our high-throughput process integrates emerging cloning technologies with state-of-the-art automation and workflow supporting bioinformatics based on Genedata Biologics Database.

Identification and Quantitation of DuoBody Bispecific IgG1 Using Mass Spectrometry and Automated Data Processing and Analysis Workflow
Ewald Van den Bremer, Ph.D., Senior Scientist, Genmab A/S

Bispecific Antibody Therapeutics
Friday, January 12 | 9:05–9:35

The characterization of bispecific antibodies (BsAbs) by mass spectrometry (MS) offers several advantages over traditional chromatographic techniques (e.g. HIC, CEX). MS provides unambiguous identification and relevant quantitative information, and combined with automated data processing and analysis, it can be employed in a high-throughput environment. We present a software solution and the related workflows that enabled us to accelerate BsAb research batch characterization and release, achieving high quality results and significant time and cost savings.

Design and Evaluation of Next-Generation Biologics for Cancer Immunotherapy
Christopher Smith, Ph.D., Senior Scientific Consultant, Biologics, Genedata

Creating Next-Generation Therapies Session
Thursday, January 11 | 11:30–12:00

Bi- and multi-specific antibodies, Ab-cytokine fusion proteins, non-Ig scaffolds, chimeric antigen receptors (CARs), engineered TCRs and TCR-based bispecific constructs can provide significant advantages for use in cancer immunotherapy. However, as highly engineered molecules they pose new design, engineering, cloning, expression, purification, and analytics challenges. Genedata Biologics enables the automated design, screening, production, and testing of large panels of these candidate therapeutic molecules and includes built-in tools for developability and manufacturability assessments.

Links:
www.chi-peptalk.com